Breaking News

Exscientia Enters Drug Discovery Collaboration with GSK

Pre-clinical collaboration focused on up to 10 targets nominated by GSK

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Exscientia has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). Exscientia will apply its AI enabled platform and combine this with GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas. Exscientia will receive research payments from GSK to undertake new discovery programs with nominated targets with the goal of delivering pre-clinical candidates. In addition to re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters